Owens & Minor Analysts Boost Their Forecasts After Q2 Results

Owens & Minor (OMI) reported worse-than-expected Q2 adjusted EPS of $0.26, missing estimates, yet its shares surged 18% to $5.47. This counterintuitive market reaction appears to be driven by the company's announcement of being in the final stages of divesting its Products & Healthcare Services segment, now classified as discontinued operations. OMI also provided FY2025 adjusted EPS guidance of $1.02-$1.07 and sales of $2.76 billion-$2.82 billion. Despite the stock's rally, multiple analysts, including BofA, Citigroup, and Baird, subsequently lowered their price targets on OMI.

Analysis

Owens & Minor (OMI) presents a complex investor narrative following its second-quarter report. The company posted a slight earnings miss with adjusted EPS of $0.26, narrowly below the $0.27 consensus estimate. Despite this, the stock surged 18% to $5.47, a reaction driven almost entirely by a significant strategic update. OMI announced it is in the final stages of divesting its Products & Healthcare Services segment, which has now been classified as discontinued operations. This move is being viewed by the market as a major positive catalyst, suggesting investors are prioritizing the potential for a more streamlined, focused company over the minor earnings shortfall. Looking forward, the company issued FY2025 guidance for adjusted EPS of $1.02-$1.07 on sales between $2.76 billion and $2.82 billion. However, a notable disconnect exists between the market's bullish reaction and Wall Street analyst sentiment. Following the announcement, analysts at B of A Securities, Citigroup, and Baird all lowered their price targets, with B of A reiterating an Underperform rating and a new target of $4.75, below the current share price. This indicates that while the divestiture is a key development, analysts are recalibrating their valuation models for the remaining entity to a lower level than the market's initial exuberance implies.

Key Decisions for Investors

• Investors should prioritize monitoring the final terms of the Products & Healthcare Services segment divestiture, as the valuation and use of proceeds will be critical determinants of OMI's future balance sheet and capital allocation strategy.
• Caution is warranted regarding the stock's 18% surge, as it contrasts sharply with multiple analyst price target reductions, suggesting the rally may be overextended until the financial impact of the restructuring is fully clarified.
• The investment thesis now shifts to the valuation and growth prospects of the remaining business; it is prudent to re-evaluate OMI based on its FY2025 guidance for continuing operations, weighing the benefits of a more focused company against the risks highlighted by the lowered analyst targets.